{"id":"allisartan-isoproxil","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL191","moleculeType":"Small molecule","molecularWeight":"422.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug blocks angiotensin II from binding to AT1 receptors on vascular smooth muscle and other tissues, preventing vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral resistance, and decreased blood pressure. Allisartan isoproxil is a prodrug that is hydrolyzed to its active form, allisartan, in the body.","oneSentence":"Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:24:50.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07174830","phase":"PHASE4","title":"Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants","status":"RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2025-09-06","conditions":"Healthy Participants","enrollment":54},{"nctId":"NCT04111419","phase":"PHASE4","title":"Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-07-01","conditions":"Atrial Fibrillation, Hypertension","enrollment":1200},{"nctId":"NCT03264352","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"XueQing Yu","startDate":"2018-02-01","conditions":"Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure","enrollment":11414},{"nctId":"NCT02893358","phase":"PHASE4","title":"Antihypertensive Treatment in Masked Hypertension","status":"COMPLETED","sponsor":"Yan Li","startDate":"2017-02-14","conditions":"Masked Hypertension","enrollment":320},{"nctId":"NCT06500689","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Essential Hypertension","enrollment":366},{"nctId":"NCT06465264","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-04-29","conditions":"Essential Hypertension","enrollment":499},{"nctId":"NCT04978649","phase":"PHASE4","title":"Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy","status":"WITHDRAWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-01","conditions":"Diabetes Mellitus, Type 2, Blood Pressure","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CEREBRAL INFARCTION"},{"count":2,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":2,"reaction":"HYPOTENSION"},{"count":2,"reaction":"RENAL IMPAIRMENT"},{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ANGINA PECTORIS"},{"count":1,"reaction":"ANION GAP INCREASED"},{"count":1,"reaction":"ARRHYTHMIA"},{"count":1,"reaction":"ARTERIAL STENOSIS"},{"count":1,"reaction":"ATRIAL FIBRILLATION"}],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xinlitan"],"phase":"marketed","status":"active","brandName":"Allisartan Isoproxil","genericName":"Allisartan Isoproxil","companyName":"Guangdong Provincial People's Hospital","companyId":"guangdong-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}